Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood natural killer cells
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord blood natural killer (NK) cells are an allogeneic cell therapy product consisting of NK cells isolated and expanded from umbilical cord blood. Unlike T cells, NK cells do not require HLA matching to prevent graft-versus-host disease (GvHD), making them a suitable off-the-shelf therapeutic option. These cells exert anti-tumor activity through the release of cytotoxic granules (perforin and granzymes) and the production of pro-inflammatory cytokines upon recognition of tumor-associated stress ligands or the absence of self-MHC class I molecules. Sun Yat-sen University Cancer Center is evaluating these cells in a Phase I clinical trial for children with high-risk, recurrent, or refractory neuroblastoma to assess safety, tolerability, and preliminary efficacy following standard multimodal treatments.
- Other names
- UCB-NK cellsumbilical cord blood-derived NK cellsumbilical cord blood natural killer cells
02
Targets
FCGR3B (Fc gamma receptor III)
Beyond the preview
Go deeper on umbilical cord blood natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood natural killer cells.